Abstract
Up to date, Alzheimer’s Disease (AD) is considered as an “urgency” for public health, since it represents one of the most dramatic causes of death in adults. The drugs currently used for AD are only symptomatic, thus not curing the pathology, but only trying to slow or delay the progression of the pathology. Moreover, there is a total lack of early identification, with only “probable’’ or ‘‘possible’’ diagnosis of AD patients. With this review, we aimed to individuate and to highlight the most promising approaches for AD therapy and diagnosis. In this view, at the cutting-edge of innovation, nanocarriers as polymeric nanoparticles, liposomes, nanoassembly and dendrimers, have been studied and investigated in order to ameliorate the detection (in vitro and in vivo) and/or the therapeutic options in AD. In this review, the most outstanding nanomedicine-driven approaches in AD imaging/detection and treatments are summarized in order to help in individuating values and criticisms. Moreover, an overview of one of the most innovative strategies in AD management, namely theranostic nanomedicine, is reported and commented.
Keywords: Alzheimer's disease, AD imaging, AD therapy, nanocarriers, theranostic nanomedicine.
Current Medicinal Chemistry
Title:Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Volume: 21 Issue: 36
Author(s): B. Ruozi, D. Belletti, F. Pederzoli, P. Veratti, F. Forni, M.A. Vandelli and G. Tosi
Affiliation:
Keywords: Alzheimer's disease, AD imaging, AD therapy, nanocarriers, theranostic nanomedicine.
Abstract: Up to date, Alzheimer’s Disease (AD) is considered as an “urgency” for public health, since it represents one of the most dramatic causes of death in adults. The drugs currently used for AD are only symptomatic, thus not curing the pathology, but only trying to slow or delay the progression of the pathology. Moreover, there is a total lack of early identification, with only “probable’’ or ‘‘possible’’ diagnosis of AD patients. With this review, we aimed to individuate and to highlight the most promising approaches for AD therapy and diagnosis. In this view, at the cutting-edge of innovation, nanocarriers as polymeric nanoparticles, liposomes, nanoassembly and dendrimers, have been studied and investigated in order to ameliorate the detection (in vitro and in vivo) and/or the therapeutic options in AD. In this review, the most outstanding nanomedicine-driven approaches in AD imaging/detection and treatments are summarized in order to help in individuating values and criticisms. Moreover, an overview of one of the most innovative strategies in AD management, namely theranostic nanomedicine, is reported and commented.
Export Options
About this article
Cite this article as:
Ruozi B., Belletti D., Pederzoli F., Veratti P., Forni F., Vandelli M.A. and Tosi G., Nanotechnology and Alzheimer's Disease: What has been Done and What to Do', Current Medicinal Chemistry 2014; 21 (36) . https://dx.doi.org/10.2174/0929867321666140716100056
DOI https://dx.doi.org/10.2174/0929867321666140716100056 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stress Myocardial Perfusion Imaging in the Emergency Department - New Techniques for Speed and Diagnostic Accuracy
Current Cardiology Reviews Aortic Arch Calcification and Mortality in Chronic Hemodialysis Patients
Reviews on Recent Clinical Trials Roles of SUMOylation in Heart Development and Cardiovascular Diseases
Current Molecular Medicine Meet Our Section Editor
Current Diabetes Reviews Protein-mediated Fatty Acid Uptake in the Heart
Current Cardiology Reviews ATP-Sensitive Potassium Channels
Current Pharmaceutical Design Advances in Antithrombotic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry A Multidisciplinary Atrial Fibrillation Clinic
Current Cardiology Reviews Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Synthesis and Antiproliferative Activity of New Polyoxo 2-Benzyl-2,3- dihydrobenzofurans and Their Related Compounds
Letters in Drug Design & Discovery Heart Score Estimation by Specialized Nurses in a Greek Urban Population
Current Vascular Pharmacology Hypotensive Effects of the Triterpene Oleanolic Acid for Cardiovascular Prevention
Current Molecular Pharmacology Editorial [Hot topic: Phosphodiesterase-5 Inhibitors and their Use in the Treatment of Urological Conditions (Executive Editor: Perimenis Petros)]
Current Pharmaceutical Design The Role of Genes (and Environmental Stress) in Depression: An Update
Current Psychiatry Reviews Effects of Music Therapy on Psychological Symptoms and Heart Rate Variability in Patients with Dementia. A Pilot Study
Current Aging Science Recent Advances on the Antiatherogenic Effects of HDL-Derived Proteins and Mimetic Peptides
Current Pharmaceutical Design A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets The Role of Trimetazidine After Acute Myocardial Infarction
Current Vascular Pharmacology Chronic Latent Magnesium Deficiency in Obesity Decreases Positive Effects of Vitamin D on Cardiometabolic Risk Indicators
Current Vascular Pharmacology The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design